Brought to you by 
TaiGen, YiChang HEC create JV in the Greater China region
27 Jan 2023
Executive Summary
TaiGen Biotechnology Co. Ltd. and YiChang HEC ChangJiang Pharmaceutical Co. Ltd. have created a Chinese joint venture to develop, manufacture, and commercialize direct-acting antiviral agents (DAAs) for treating chronic hepatitis C virus (HCV) in mainland China, Taiwan, Hong Kong, and Macau.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TaiGen, YiChang HEC create JV in the Greater China region
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice